Daiichi Sankyo’s VANFLYTA® Approved for Acute Myeloid Leukaemia in EU
VANFLYTA® (quizartinib) is now the first FLT3 inhibitor approved in the European Union (EU) specifically for the treatment of patients
Read moreVANFLYTA® (quizartinib) is now the first FLT3 inhibitor approved in the European Union (EU) specifically for the treatment of patients
Read moreSwiss pharma giant Roche has entered an agreement to purchase Telavant Holdings, a Roivant company, owned by Roivant Sciences Ltd.
Read moreElly Lilly announced plans to acquire POINT Biopharma, with the strategic move set to boost Lilly’s oncology capabilities with next-generation
Read moreSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in therapies for central nervous system disorders and rare diseases, has unveiled
Read moreAmerican biotech company Ginkgo Bioworks announced a new collaboration with Pfizer focused on the discovery of RNA-based drug candidates. The
Read moreIn a significant milestone for the pharmaceutical industry, Merck KGaA has established itself as the pioneer Contract Testing, Development, and
Read moreThe Biosimilar Tyruko® has been approved for all indications of reference medicine, as the first and only biosimilar to treat
Read moreOrano Med, a clinical-stage biotechnology company that develops the next generation of targeted therapies against cancer using the unique properties
Read morePeptiDream Inc., a publicly traded biopharmaceutical company headquartered in Kanagawa, Japan, led by President and CEO Patrick C. Reid, has
Read moreThe partnership with Samsung Bioepis Grants Novartis’ generic-drugs unit Sandoz exclusive commercialization rights for biosimilar SB17 Ustekinumab in Europe and
Read more